Editor's note

This ExpertREACT article was originally published on 20 September 2010 following the 50th ICAAC conference in Boston (12-15 September 2010). Conference data and pipeline statuses described reflect the state of knowledge at that date.

Novel influenza immunity insights

The 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) brought approximately 10,000 delegates to Boston from 12-15 September 2010, with vaccines and vaccination featuring prominently throughout the agenda. In the opening Keynote Session, Professor Peter Doherty (University of Melbourne) discussed influenza virus immunity with a particular focus on virus-specific CD8+ T-cells - the "hitmen" - and their recognition of influenza A internal epitopes. The discussion raised the possibility of novel broadly-protective vaccine approaches that might incorporate T-cell priming superior to conventional haemagglutinin-focused vaccines. Prof Doherty also cautioned against underestimating H1N1, citing 10,000 excess deaths and notably increased ICU admissions in pregnant women.

In the Vaccines for Global Health session, GSK Biologicals' RTS,S pre-erythrocytic malaria vaccine received significant attention. RTS,S had by then been administered to approximately 3,000 infants and children (approximately 9,000 doses), with a favourable safety profile and Phase III initiated at 11 clinical centres in May 2009. Regina Rabinovich highlighted that only combination approaches including transmission-blocking vaccines (TBVs) - such as AnAPN1 from JHSPH/Sabin Vaccine Institute - could achieve the long-term goal of malaria eradication, given TBVs' theoretical capacity to halt mosquito-to-human spread.

RTS,S Phase III
11 sites
Phase III initiated at 11 clinical centres in May 2009; approximately 3,000 infants/children vaccinated (9,000 doses) as of ICAAC 2010

TB, pneumococcal and meningococcal highlights

Willem Hanekom (Cape Town) reviewed current TB vaccine development with emphasis on new BCG replacement vaccines and BCG booster approaches, reflecting the growing momentum in a field long characterised by slow progress. The Vaccines for Global Health session also covered meningococcal A vaccine development for sub-Saharan Africa, where serogroup A accounts for the majority of epidemic meningococcal disease in the "meningitis belt". Pneumococcal vaccine epidemiology data presented at the conference showed that Prevnar (PCV-7) had achieved a ~92% reduction in vaccine-type IPD in the elderly through herd immunity effects - an important demonstration of indirect population protection that would need to be evaluated carefully as PCV-13 was introduced.